Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 November 2005

Inherited antithrombin deficiency and end stage renal disease.

Tomohiko Hara, Katsusuke Naito

Med Sci Monit 2005; 11(11): RA346-354 :: ID: 430402

Abstract

Antithrombin is a potent inhibitor of the coagulant effect of thrombin.In the latter half of 20(th) century, many families have been described in which an autosomaly dominantinherited antithrombin deficiency has caused severe venous thromboembolic disease in successive generations.The important complication is severe venoocclusive disease by deep venous thrombus. Some inherited antithrombindeficient patients developed renal failure because of fibrin deposition in the kidney glomeruli or renalvein thrombus, and therefore the need for replacement therapy for end stage renal disease (ESRD). Althoughan inherited antithrombin deficiency with renal failure is rare, prevention against renal failure insuch patients, and their renal replacement therapy for ESRD are important. Proteinuria decreases plasmaantithrombin level leading to more severe hyper-coagulation state. Therefore early in renal disease,it may be prudent for adaptation of anti-coagulation therapy even if recurrent thrombosis has not occurred.All replacement therapy (hemodialysis, transplantation or peritoneal dialysis) for ESRD are availablefor such thrombophilic disorders. Anticoagulation agents working without aggravation of antithrombineffects (Argatroban, Nafamostat mesilate etc.) are useful for hemodialysis. The renal allograft recipientswith thrombophilia seem to be at risk of developing an acute rejection or other vascular event. Peritonealdialysis is potentially a good adaptation for such thrombophilic disorders. However which therapy hasthe best mortality and morbidity outcomes is not clear. Physicians and Surgeons must pay attention tothe coagulation state and thrombophilia in ESRD patients, give strong consideration for adequate anti-coagulationtherapy and review the best renal replacement modality for each patient.

Keywords: Antithrombins - metabolism, Antithrombin III Deficiency - genetics, Kidney Failure, Chronic - therapy, Kidney Transplantation, Renal Dialysis, Venous Thrombosis - therapy

Add Comment 0 Comments

Editorial

01 March 2024 : Editorial  

Editorial: First Regulatory Approvals for CRISPR-Cas9 Therapeutic Gene Editing for Sickle Cell Disease and Transfusion-Dependent β-Thalassemia

Dinah V. Parums

DOI: 10.12659/MSM.944204

Med Sci Monit 2024; 30:e944204

0:00

In Press

18 Mar 2024 : Clinical Research  

Sexual Dysfunction in Women After Tibial Fracture: A Retrospective Comparative Study

Med Sci Monit In Press; DOI: 10.12659/MSM.944136  

0:00

21 Feb 2024 : Clinical Research  

Potential Value of HSP90α in Prognosis of Triple-Negative Breast Cancer

Med Sci Monit In Press; DOI: 10.12659/MSM.943049  

22 Feb 2024 : Review article  

Differentiation of Native Vertebral Osteomyelitis: A Comprehensive Review of Imaging Techniques and Future ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943168  

23 Feb 2024 : Clinical Research  

A Study of 60 Patients with Low Back Pain to Compare Outcomes Following Magnetotherapy, Ultrasound, Laser, ...

Med Sci Monit In Press; DOI: 10.12659/MSM.943732  

Most Viewed Current Articles

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750